Minimal residual disease (MRD) (that is, isolated tumor cells (ITC) in bone marrow) may be the source of potentially fatal overt distant metastases in solid tumors even years after primary treatment. MRD can be detected by immunohistochemical methods using antibodies directed against cytokeratins, cell-surface markers, or molecular, PCRbased techniques. Among solid tumors, the clinical relevance of MRD has been most extensively studied in breast cancer patients. Recently, the highest level of evidence for the prognostic impact of MRD in primary breast cancer was reached by a pooled analysis comprising more than 4,000 patients, showing poor outcome in patients with MRD at primary therapy. Yet, clinical application of MRD detection is hampered by the lack of a standardized detection assay. Moreover, clinical trial results demonstrating the benefit of a therapeutic interference derived from bone marrow status are still missing. Recent results suggest that, in addition to its prognostic impact, MRD can be used for therapy monitoring or as a potential therapeutic target after phenotyping of the tumor cells. Persisting MRD after primary treatment may lead to an indication for extended adjuvant therapy. In a pooled analysis, bone marrow aspirates of 726 patients from academic breast cancer units in Oslo (n = 356), Munich (n = 228) and Tuebingen (n = 142) were analyzed during recurrence-free follow-up at a mean interval of 31.7 months after primary diagnosis of breast cancer pT1-4, pN0-3 pM0. Persistent ITC were detected in 15.4% of the patients (n = 112). The Kaplan-Meier estimate for mean distant relapse-free survival estimate was 163.6 months in patients with negative bone marrow status and 105.2 months in patients with positive bone marrow status. Patients without evidence of persistent ITC had a significantly longer overall survival (165.6 months), than patients with positive bone marrow status (103.3 months, P < 0.0001).
In multivariate Cox regression analysis, allowing for bone marrow 
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signature (genomic profile) was obtained in node-negative patients with a representative tumor sample; node-positive patients were excluded. Between 2004 and 2006, 812 patients were enrolled and 427 (53%) genomic profiles were obtained. The remaining 385 (47%) patients were excluded mainly because of node-positive disease (22%). The logistics of obtaining fresh-frozen material from the tumor has gone very well in each of the participating hospitals. Approximately 50% of the tumors were shown to have a good prognosis signature.
Another area of research is to identify gene expression signatures associated with the response to chemotherapy. Within a singleinstitution prospective phase II trial, patients with locally advanced breast cancer received six courses of either doxorubicin-cyclophosphamide (AC) (n = 25) or doxorubicin-docetaxel (AD) (n = 24) containing neoadjuvant chemotherapy. Gene expression profiles were generated from core needle biopsies obtained before treatment and correlated with the response of the primary tumor to the chemotherapy administered [3] . Additionally, pretreatment gene expression profiles were compared with those in tumors remaining after chemotherapy (n = 15). Eleven (22%) of the 49 patients showed a (near) pathological complete remission of the primary tumor after treatment. No gene expression pattern correlating with response could be identified for all patients as well as for the AC-treated or AD-treated group separately. The comparison of the pretreatment biopsy and the tumor excised after chemotherapy revealed differences in gene expression in those tumors that showed a partial remission but not in tumors that did not respond to chemotherapy. No gene expression profile predicting the response of primary breast carcinomas to AC-based or AD-based neoadjuvant chemotherapy could be detected in this study. We are currently expanding the series of patients in this neoadjuvant chemotherapy study. We conclude that gene expression profiling is a method that has greatly accelerated the identification of prognostic and predictive factors in breast cancer and will lead to novel diagnostic tests that can be reliably implicated in clinical practice. Many single-gene molecular markers have been evaluated as predictors of response to specific regimens. However, no reliable and routinely used molecular chemotherapy response predictors exist today. Molecular markers of proliferative activity remain nonspecific predictors of chemotherapy sensitivity in general. Multidrug-resistance transport proteins, p53 gene mutations, and defects in apoptotic pathways remain highly controversial as predictors of response or resistance to particular drugs. To date, the strongest (although still indirect) evidence supporting a molecular predictor of response to a particular regimen comes from a retrospective subset analysis of a variety of studies that showed a link between topoisomerase II amplification and increased sensitivity to anthracyclines. However, the best methodology for determining amplification of topoisomerase II and the appropriate cut-off value to distinguish between individuals with and without amplification have not been established. Several small studies provided 'proof-of-principle' that the gene expression profile of cancers that are highly sensitive to chemotherapy is different from that of tumors resistant to treatment. Table 1 (overleaf) presents a summary of the current literature. The most exciting possibility implicit to gene expression profiling-based diagnostic tests is that multiple predictors could be applied to a single data set. It is currently technically feasible to perform gene expression profiling on a single biopsy and assess prognosis using a 76-gene, or 70-gene signature, determine the ER and HER-2 status by measuring receptor mRNA levels, predict endocrine sensitivity among the ER-positive patients and estimate the probability of response chemotherapy. Several unique surgical issues arise in the management of patients who are candidates for neoadjuvant systemic therapy. These involve the original diagnostic assessment of the extent of disease in the breast and axilla, the preoperative planning, and ultimately the surgical management of the primary breast tumor and that of axillary lymph nodes. Careful consideration of these issues is crucial in order to maximize local control of the disease, while minimizing the extent of the required surgical resection and the ensuing surgical morbidity. Adequate diagnostic assessment with core needle biopsy before the initiation of neoadjuvant systemic therapy ensures the presence of invasive carcinoma and provides adequate material for routine biomarker evaluation (such as ER, PR and HER-2 neu), while minimally disturbing the primary breast tumor. Consideration should also be given in assessing the status of axillary nodes by minimally invasive techniques such as ultrasound of the axilla and fine needle aspiration of suspicious nodes. Optimal preoperative planning aims at accurately determining the patterns of primary tumor shrinkage and the amount and location of any residual disease in the breast. Surgical treatment after neoadjuvant systemic therapy focuses on the management of the primary breast tumor and that of axillary lymph nodes. Regarding the primary breast tumor, several studies have shown that neoadjuvant systemic therapy converts a proportion of mastectomy candidates to candidates for breast-conserving surgery. Neoadjuvant systemic therapy can also decrease the amount of breast tissue that needs to be removed at lumpectomy even in patients who are lumpectomy candidates at presentation. Neoadjuvant systemic therapy (primarily neoadjuvant chemotherapy) downstages axillary lymph nodes in up to 30-40% of the patients. Although this observation was of little clinical significance when axillary node dissection was the sole method for staging the axilla, the development and validation of sentinel lymph node biopsy has provided an additional potential advantage for neoadjuvant chemotherapy; that is, the possibility of decreasing the extent and morbidity of axillary surgery. This approach is, naturally, predicated on the premise that sentinel node biopsy is feasible and accurate following neoadjuvant chemotherapy. Until recently, only small, single-institution studies have examined the efficacy of lymphatic mapping and the accuracy of sentinel node biopsy after neoadjuvant chemotherapy with significant variability in the rate of sentinel node identification and in the rate of false negative sentinel node [1] . When these studies are examined collectively [1, 2] or when larger, multicenter data sets are analyzed [3] , however, sentinel node biopsy after neoadjuvant chemotherapy appears to have similar performance characteristics to those of sentinel node biopsy before systemic therapy [4] [5] [6] . Some have proposed that candidates for neoadjuvant systemic therapy should have a sentinel node biopsy before, rather than after, neoadjuvant systemic therapy so that information on the status of the axillary nodes is obtained without the potential confounding effects of systemic treatment, and sentinel node-negative patients can avoid axillary dissection [7] [8] [9] . Although this approach may be useful in patients who will not need systemic therapy (that is, chemotherapy) if the sentinel node is negative, it is not generally useful for the majority of candidates for neoadjuvant systemic therapy, for whom little -if anything -is to be gained by knowing the pathologic nodal status upfront. In addition, this approach commits patients to two surgical procedures and does not take advantage of the down-staging effect of neoadjuvant chemotherapy on the axillary nodes. patients without surgical therapy (P = 0.002). TTFP was prolonged in the surgical group, adjusted HR 0.639 (P = 0.03). The HR for overall survival in the surgical group was 0.724 (P = 0.160). Notably, in women with controlled chest walls we observed an overall survival benefit with a HR of 0.418 (P < 0.0002).
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Conclusion Recent retrospective studies suggest that surgical resection of the primary tumor in women who also have distant disease may be beneficial [1] [2] [3] . These are remarkably consistent in the magnitude of the survival advantage, with a hazard ratio of about 0.6 when surgical intervention is used. There is a paucity of data supporting the assumption that surgical resection will maintain a disease-free chest wall. A study of women with in-breast recurrence of breast cancer and synchronous distant metastases found that women undergoing resection were more likely to avoid uncontrolled chest-wall disease and to survive longer [4] . Our study at NMH (the largest reported to date examining this issue) finds that maintenance of a disease-free chest wall is associated with improved survival. This further emphasizes the need for prospective randomized trials to establish the role of local therapy in the setting of metastatic breast cancer. The controversy today is that we continue to undergo an important evolution in our approach to breast reconstruction because of the identified advantage of the addition of postmastectomy radiation therapy to mastectomy and chemotherapy. The inability to determine which patients will require postmastectomy radiation therapy, especially which patients with early-stage breast cancer, has increased the complexity of planning for immediate breast reconstruction. There are two potential problems with performing an immediate breast reconstruction in a patient who will require postmastectomy radiation therapy. One problem is that postmastectomy radiation therapy can adversely affect the aesthetic outcome of an immediate breast reconstruction [1] [2] [3] . The other potential problem is that an immediate breast reconstruction can interfere with the delivery of postmastectomy radiation therapy. Because radiation therapy is one of the most important considerations affecting the timing and technique of breast reconstruction, plastic surgeons and radiation oncologists must work together to maintain an appropriate balance between minimizing the risk of recurrence and providing the best possible aesthetic outcome. Our experience at the MD Anderson Cancer Center and many of the other experiences reported in the literature indicate that breast reconstruction should probably be delayed in patients who are known preoperatively to require postmastectomy radiation therapy [2, 4] . Considering, then, our evolving approach for early breast cancer patients who want immediate breast reconstruction but are at higher risk for postmastectomy radiation therapy and likely delayed reconstruction, our updated 'delayed-immediate' [5] Results The NAC necrosed totally in 26 cases (3.3%) and partially in 49 cases (6.3%), and was removed in 36 cases (4.6%). Thirteen infections (1.6%) were observed and 32 (4.14%) prostheses removed. The median rating of the patients for global cosmetic results on a 0 (worst) to 10 (excellent) scale was 8. The surgeon in charge of the follow-up has given the same rating. A radio dystrophy was observed on the areola in 5.1% of the patients. The sensitivity of the NAC recovered slowly and partially in only 30% of the cases. Twelve local recurrences (1.5%) occurred in an average follow-up period of 18 months (range 1-61 months). Most recurrences were located far from the nipple areola site, outside the radiated field. Two recurrences were Paget disease associated with an in situ carcinoma. Overall, we observed 23 metastases and three deaths. Sixty-eight per cent of patients were satisfied with their reconstructed breast and 97% were satisfied with having preserved the NAC.
Introduction
Conservative treatment is now well accepted for a majority of breast cancers and is performed in around 70-80% of cases [1] . However, mastectomy remains indicated in at least 20% of patients. An important improvement resulted from the skin-sparing mastectomy technique, validated by several publications [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . The preservation of the skin envelope has favoured the quality of the breast reconstruction, and breast reconstructive surgery has made important progress, providing more natural shape. However, despite the reconstruction, patients often deplore a feeling of mutilation. The nipple areola complex (NAC) Available online http://breast-cancer-research.com/supplements/9/S1 appears an identity mark of the breast [12] . Several authors have evaluated the risk of nipple areola involvement and investigated the possibility of nipple areola preservation [13] [14] [15] [16] [17] [18] . Focusing on such risk, and the possible cancer recurrence in the breast tissue preserved beneath the NAC for the blood supply, we proposed to combine the subcutaneous mastectomy technique with intraoperative radiotherapy with electrons (ELIOT), previously trialled in breast-conserving treatment [19] . The preliminary results of the 'nipple sparing mastectomy' (NSM) were published in 2003 [20] . Today, we report the results of 773 NSMs performed at the European Institute of Oncology.
Materials and methods
From March 2002 to March 2007, 898 patients were invited to undergo a NSM. The inclusion criteria were primary tumours located at least 1 cm outside the areola margins, an absence of nipple retraction or bloody discharge, and an absence of retro areola microcalcifications. Multifocality was not a cause for exclusion, provided that all the tumour sites were distant from the areola. Invasive as well as in situ carcinomas were included. Patients were excluded at the time of the operation when the frozen examination of the retro areola tissue had been positive for carcinoma: in these cases, ELIOT was not delivered and the NAC was removed. Among the 898 cases, 98 were excluded, mainly because of the positive extemporaneous examination and in several cases because of the poor blood supply requiring the NAC removal. Fifty-one candidates were excluded because no radiotherapy was delivered, most often when the blood supply was poor and the risk of necrosis very high. Finally, 749 patients underwent a NSM, among whom 24 had a bilateral NSM. The mean patient age was 46 years (range 20-73 years). Seventy-five per cent of the patients have a mean follow-up of 18 months (range 1-61 months).
The surgical technique has already been described [20] . Breast reconstruction was achieved with a definitive prosthesis in 689 cases (89%) and with an expander in 185 (24%). Only six patients underwent a reconstruction with an autologous transverse rectus abdominis myocutaneous and one with an autologous Latissimus dorsi.
Once the glandular tissue has been removed and the frozen section of the retro areola tissue proved free of cancer, ELIOT was performed on the NAC area. The ELIOT technique has already been described [21] [22] [23] [24] . In our technique, 16 Gy were delivered on the NAC in one shot with lead and aluminium disk protection of the pectoralis muscle and thoracic wall (see Figure 1 ). However, in 145 cases, the same radiotherapy was postponed to the following day, due to technical problems with the machine in the operating room. Sensitivity, colour, radio dystrophy, position and symmetry, and global evaluation by the surgeon and the patient, were rated according to a scale (0-10), 10 indicating the best results. (The results were rated poor when rated from 0 to 3, fair from 5 to 6 and good or excellent from 7 to 10.) Local recurrences, distant metastases and death were also recorded. A psychological study was conducted concomitantly. A detailed questionnaire was sent to the patients 1 year after the operation to evaluate the degree of satisfaction. The statistic analysis of psychological results was performed with the chi-square test and exact Fisher test. Results NAC total necrosis was observed in 26 cases out of 773 NSMs (3.3%). Partial necrosis was observed in 49 cases (6.3%). The NAC was removed in 36 cases (4.6%). The definitive histology of the 773 NSMs was invasive carcinoma in 63% and in situ carcinoma in 37%. In 53 cases (6%), the definitive histology of the retro areola tissue returned positive for carcinoma (invasive in 35 cases and in situ in 18 cases). Thirteen infections (1.6%) were observed in the immediate postoperative period; 32 prostheses were removed (4.1%). A capsulotomy has been required in 137 cases (17.7%). Cosmetic results and sequelea were evaluated by the surgeon in charge of the follow-up according to the scale previously mentioned. The average evaluation of the sensitivity of the areola and the periareolar area was 2/10. Thirty per cent of the patients recovered some kind of sensitivity in several months. The colour of the areola was judged 8/10. The radio dystrophy was absent in most cases: 9/10. A radio dystrophy such as telangiectasia has been observed in 5.1% of the cases. The symmetry of the breasts was evaluated well in most Breast Cancer Research Vol 9 Suppl 1 VII Madrid Breast Cancer Conference 
Cancer results
Despite the frozen section performed underneath the NAC to eliminate the cases with positive results, the final histology of the retro areola tissue was positive in 53 (6.8%) cases, among which 35 were invasive carcinomas (66%). However, the NAC has been preserved in most cases when the final examination returned positive, taking into account the intraoperative radiotherapy to avoid recurrences. The secondary removal was due to local necrosis. Twelve local recurrences were observed. Two were located on the NAC and the 10 others at a distance from the radiated area, usually in the same area of the tumour location. Both recurrences on the NAC were a DCIS associated with a Paget disease on the nipple. No recurrence on the NAC was observed in the group of patients with persistent positive histology. Twenty-three cases of distant metastases and three deaths were observed in our series. The psychological study was completed for 159 patients who had at least 1 year follow-up and who answered our questionnaire. Ninetyseven per cent of the patients interviewed declare being very satisfied with the appearance of the breast after the NSM. No patient regretted having undergone reconstructive surgery, and 91.5% agreed with the mutilation being decreased by having preserved the NAC. Similarly, 93% of women responded that conserving the nipple aided in facing illness, and only 1.6% expressed a total dissatisfaction. Discussion Our study on 773 skin-sparing mastectomies performed at the European Institute of Oncology confirms the feasibility of the procedure, with a majority of good results after the preservation of the NAC. However, a partial or total NAC necrosis due to insufficient blood supply was observed in 9.7% of the cases. Moreover, 6.6% of the final retro areola histology return positive while it was observed negative at the frozen section. Such results could be improved with a better selection of the NSM, if we cancel the cases requiring an extensive retro areola tissue removal and if we change the surgical indications of the reconstruction in cases of large breast, more often using autologous tissue reconstruction. Concerning the retro areola free margins, we should verify with more accuracy the clinical proximity between the tumour and the NAC. A partial or global return of the NAC sensitivity was present in only 30% of the patients. As expected, the return is incomplete and takes months to happen [25] . The risk of radio dystrophy is low with such intraoperative radiotherapy at the level of 16 Gy. Seven per cent of the patients had a severe or moderate radio dystrophy, but a mild pigmentation was observed in around one-third of the women with at least 1 year follow-up. Two in situ local recurrences were observed on the preserved NAC, which is reassuring although the median follow-up is only 18 months. A longer follow-up is required to prove the efficacy of the intraoperative radiotherapy. The dose of ELIOT chosen to reduce the recurrence risk could be questioned [20] [21] [22] [23] [24] . The single application of 16 Gy corresponds to the classic fractioned radiotherapy of 45 Gy for tumour cells and of 70-80 Gy for late responding normal tissue. This dose should be sufficient to sterilise more than 90% of the residual cancer cells, and to obtain an acceptable risk (less than 5%) of severe late complications (necrosis). However, the percentage of patients with positive persistent carcinoma behind the NAC in our series justifies ELIOT, although other authors advocate the possibility of NAC preservation without ELIOT [13, [26] [27] [28] [29] . Finally, the primary goal of the NSM is the psychological improvement of patients requiring a mastectomy. The preliminary results of the questionnaire report a high level of satisfaction and confirm the psychological importance of NAC conservation. PBI allows reducing the radiation field to only the initially involved quadrant of the breast and significantly shortens the duration of radiation therapy. This may represent the possibility of overcoming constraints such as accessibility to the radiation therapy centres, and the socioeconomic impact on the working life and on the personal habits of the patient. PBI seems to have a positive impact on patients' quality of life. Another important advantage is the avoidance of interactions with systemic therapy that may determine delays in the initiation or in the carrying out of the conventional treatment. These possible benefits must be balanced with the potential risk of recurrence within the untreated tissue in the breast receiving PBI as well as the unknown long-term cosmetic results with the accelerated techniques. Significant practical considerations also include the choice of technique, interstitial brachytherapy (high dose-rate versus low doserate), balloon-based brachytherapy (MammoSite ® ), external beam (3D-conformal versus intensity modulated radiation therapy), and intraoperative irradiation (electrons versus low-energy X-ray device). The choice of the technique has an impact on the schedules and dose-rate that can be used, on the volume that can be irradiated and on the dose homogeneity achievable. Patient selection also remains uncertain, including questions regarding age exclusions, applicability with various primary tumour sizes, hystopathological features, the tumour-free margin and amount of tumour near the margins, and negative (including micrometastasis) or positive axillary lymph node status (up to three or more [1] . For endocrine-sensitive breast cancer, several large randomized trials have shown that third-generation aromatase inhibitors, can reduce the risk of relapse of early breast cancer in comparison with tamoxifen. Nowadays, aromatase inhibitors administered up front, as a switch after 2-3 years of tamoxifen or as extended treatment after 5 years of tamoxifen represent the standard treatment in postmenopausal women. As anthracycline and taxanes are the most active cytotoxic agents in breast cancer, anthracycline/taxanecontaining regimens are becoming the mainstay of adjuvant chemotherapy. Finally, the growing understanding of the biology of breast cancer cells led to identification of key molecular points that represent possible therapeutic targets. Trastuzumab, the monoclonal antibody against the HER-2 receptor, is approved for the treatment of high-risk early breast cancer overexpressing HER-2 and represents the standard treatment in these patients. With increasing use of very active drugs in the adjuvant setting, there is a greater need for effective Available online http://breast-cancer-research.com/supplements/9/S1 S12 therapy at the time of relapse [2] . In endocrine-sensitive breast cancer, sequencing data for anastrozole and tamoxifen have shown that tamoxifen is likely to be effective after progression on anastrozole. Moreover, in recent years Fulvestran, a selective ER downregulator acting as a pure antiestrogen agent, has been developed. Tamoxifen, Fulvestran or an aromatase inactivator are possible options after failure of adjuvant aromatase inhibitors. At present, it is not possible to define the optimal sequence of these endocrine agents. In endocrine-resistant disease, a treatment-free interval (TFI) >12 months after adjuvant chemotherapy has been shown to be an important factor for determining sensitivity to drug rechallenge. If the tumor has been exposed to an anthracycline and a taxane in adjuvant setting and the TFI is >12 months, the re-treatment with the same agents may be an option [3] . Methods The results of key randomised trials addressing these issues are reviewed. Results In the P24 trial for patients not suitable for conservative surgery, neoadjuvant letrozole was shown to achieve a significantly greater clinical overall response rate than tamoxifen (56% versus 36%, P < 0.001) and a significantly better incidence of breast-conserving surgery (45% versus 35%, P = 0.02). In the IMPACT trial, neoadjuvant anastrozole was compared with tamoxifen and the combination (three arms, equivalent to adjuvant ATAC). No significant difference in clinical overall response was seen between the three arms although breastconserving surgery was considered feasibly significantly more often with anastrozole (46%) than with tamoxifen (22%) or with the combination (26%) (P = 0.03). In the PROACT trial, neoadjuvant anastrozole achieved a higher clinical overall response rate than tamoxifen (50% versus 40%) but this difference was not significant (in the endocrine therapy alone group -excluding patients also treated with chemotherapy). Breast-conserving surgery was achieved significantly more often with anastrozole (43% versus 31%, P = 0.04). The optimum duration of neoadjuvant endocrine therapy prior to surgery has not been established but circumstantial evidence suggests that it is at least 4 months, and probably longer. In the P24 trial and the IMPACT trial, patients with higher levels of ER expression had a significantly higher chance of clinical response. Likewise in both trials, aromatase inhibitors appeared strikingly more effective than tamoxifen in the subgroup of patients with HER2-positive, ER-positive tumours.
In the IMPACT trial, the change in proliferation rates after 2 weeks of treatment as measured by Ki67 was significantly greater for anastrozole than for tamoxifen or the combination, reflecting results in the adjuvant ATAC trial, and suggesting that Ki67 might be a better marker for long-term outcome than clinical response. Likewise, longterm follow-up of the IMPACT trial showed that the absolute level of Ki67 suppression after 2 weeks of neoadjuvant endocrine therapy significantly correlated with long-term disease-free survival outcome, and more so than baseline pre-treatment Ki67. Changes in expression of > 2,800 genes were observed after 2 weeks of aromatase inhibitor therapy. Conclusion These results suggest that neoadjuvant endocrine therapy is an effective clinical strategy to reduce the need for mastectomy in postmenopausal women with large hormone receptor-positive breast cancer. Short-term changes in molecular markers may be superior to clinical response in predicting long-term outcome, and this hypothesis is being further tested in a large prospective randomised trial. The aims of treatment with chemotherapy for MBC are: to prolong survival; to relieve symptoms; to improve and maintain quality of life; and to delay disease progression. Only a small minority of MBC chemotherapy trials has shown a significant survival benefit, and to some extent this is explained by the multiple lines of potential further therapy following completion of the trial. Survival is therefore an uncertain endpoint in MBC trials. Symptom improvement has been shown to correlate with response rate in one trial but this important endpoint is not used often enough. Quality-of-life endpoints are appropriate in principle, but in reality many trials have shown a poor correlation with outcome, suggesting that this tool may be relatively insensitive in this context. Time to disease progression is a much used and important endpoint because it takes into account the fact that symptom relief and prolonged survival relate not just to patients achieving objective response, but also to those with minor response or stable disease. Specific issues relating to chemotherapy for MBC include the following. There is evidence from older trials supporting the principle that endocrine therapy should be used before chemotherapy in patients with nonlife-threatening hormone-receptor-positive disease. Patients whose primary is HER2-unknown should have this checked at the time of relapse to determine whether trastuzumab should be given in addition to chemotherapy. Ideally, patients with primary HER2-negative disease should have metastatic disease rechecked since there is evidence of HER2-positive conversion in up to 25% of such patients. The choice of combination versus single-agent sequential chemotherapy is a complex one. The weight of current evidence suggests no significant survival difference with the combination, and this may be associated with more toxicity. There is no absolute answer here; choice depends on the nature of the drugs being used. Vascular endothelial growth factor (VEGF), a potent angiogenic factor, has been reported to be associated with a poor prognosis in primary breast cancer and other solid tumours [1] . VEGF was observed to be one of the most important mediators of tumour angiogenesis in human breast cancer and was the only one linked to poor relapse-free survival [2] . VEGF affects tumour growth and metastasis in many forms of breast cancer, including invasive/noninvasive, node-negative/node-positive, inflammatory and metastatic disease. Also, VEGF expression has been observed across a number of disease-related variables, including hormonal and HER-2 status. A complex relationship between oestrogen, the oestrogen-receptor subtypes, and VEGF has been seen in preclinical breast cancer models. Oestrogen modulates VEGF expression at the gene transcriptional level [3] . VEGF expression in breast cancer cells promotes oestrogen-independent tumour growth in ovariectomized mice and VEGF-stimulated neovascularization, and contributed to tumour growth in both oestrogen-treated and nonoestrogen-treated mice. Tumour growth was highest in VEGF-expressing mice treated with oestrogen [4] .
SYMPOSIUM V Advances in Metastatic Disease
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In multiple prospective and retrospective studies assessing blood and tumour samples in lung cancer patients, VEGF and angiogenesis have been associated with larger tumour size, increased rate of metastasis, recurrence of disease and poorer overall and disease-free survival [5] [6] [7] . Bevacizumab is a humanized recombinant antibody that prevents VEGF receptor binding, and inhibits angiogenesis and tumour growth. In patients receiving an irinotecan plus fluorouracil/leucovorin regimen for first-line treatment of metastatic colorectal cancer, the addition of bevacizumab significantly increased overall survival. In the second-line treatment of advanced colorectal cancer, patients who received bevacizumab in combination with a fluorouracil/leucovorin plus oxaliplatin (FOLFOX4) regimen had an overall survival time 2 months longer than that in patients receiving FOLFOX4. Bevacizumab has been tested in many tumours, proving efficacy when added to almost any chemotherapy regimen. It has been hypothesized that there are three main mechanisms by which bevacizumab exerts its antitumour activity: regression of existing tumour microvasculature, normalization of surviving mature tumour vasculature and inhibition of vessel regrowth and neovascularization as an effect with continuous treatment [8] .
Based on preclinical findings that have shown the activity of bevacizumab in breast cancer, bevacizumab monotherapy was tested in a phase I/II dose escalation trial (AVF0776g) in metastatic breast cancer (MBC) with three doses (3, 10 and 20 mg/kg every 2 weeks) in 75 patients who had relapsed following at least one conventional chemotherapy regimen for metastatic disease. Combining data from the three arms, the overall response (OR) rate was 6.7%, the median duration of response (DR) was 5.6 months and overall survival (OS) was 10.2 months. Bevacizumab was well tolerated although four patients presented with headache with nausea and vomiting at the higher dose (dose limiting toxicity). Comparison of data from the three study arms indicated that a bevacizumab dose of 10 mg/kg every 2 weeks produced the best therapeutic ratio in this population of heavily pretreated patients [9] . Bevacizumab has since been studied in several phase II trials with different chemotherapy regimens (docetaxel, vinorelbine), targeted agents (trastuzumab, erlotinib) and hormonal therapies (letrozol), showing encouraging results and acceptable toxicity profiles in these combinations. Nowadays, there is evidence for efficacy of bevacizumab from two phase III trials (AVF2119g and E2100). The first phase III trial published (AVF2119g) compared a combination of bevacizumab (15 mg/kg every 3 weeks plus capecitabine 2,500 mg/m 2 daily for 2 weeks of a 3-week cycle) versus capecitabine alone. A total of 462 women with MBC previously treated with an anthracycline and a taxane were randomized to any of the study arms. The primary study endpoint was progression-free survival (PFS) and secondary endpoints included the OR rate, DR and OS. There was no significant difference in PFS between the two arms. The proportion of progression-free patients at 6 months was 33.8% for the Xeloda-alone arm and 33.0% for the Xeloda plus bevacizumab arm. Median PFS was 4.17 and 4.86 months, respectively (HR = 0.98, P = 0.857). Overall survival data for the Xeloda-alone arm (14.5 months) compared with the Xeloda plus bevacizumab arm (15.1 months) was also not significant. Although the addition of bevacizumab to capecitabine did improve PFS nor OS, there was a significant increase in the OR rate in the capecitabine plus bevacizumab arm compared with the capecitabine-only arm when the data were analysed both by investigators (30.2% versus 19.1%; P = 0.006) and by an independent review facility (19.8% versus 9.1%; P = 0.001). However, no significant differences in PFS or in OS were found between the two arms. The combination was found to be well tolerated, with no increase in the frequency or severity of capecitabinerelated adverse events in the bevacizumab-containing arm [10] . In this study, although the addition of bevacizumab to capecitabine did not improve PFS (the primary endpoint), the OR rate doubled.
There have been a number of reasons hypothesized that could explain these observations. First of all, it has been demonstrated that VEGF inhibition is more effective in earlier disease, since in advanced disease there are also other angiogenic factors that are overexpressed [11] .
Another reason could be that patients were heavily pretreated, having received both an anthracycline and a taxane prior to entering the trial. The other phase III trial (E2100) is an ongoing open-label, phase III trial in which bevacizumab is being evaluated in combination with weekly paclitaxel as first-line therapy for MBC. Patients recruited to this trial are less heavily pretreated than patients in AVF2119g. A total of 722 patients have been randomized to one of two arms: paclitaxel 90 mg/m 2 alone every week for 3 weeks followed by 1 week without treatment or paclitaxel plus bevacizumab 10 mg/kg every 2 weeks. No crossover is permitted in this trial. The objectives are to compare PFS, the OR rate and OS between the arms. Preliminary results from the first preplanned interim analysis showed a significant increase in median PFS in patients receiving bevacizumab plus paclitaxel compared with paclitaxel alone (11.4 versus 6.11 months; P < 0.0001). This PFS result was obtained following 89% of the required events. The OR rate for all patients was 29.9% (bevacizumab/paclitaxel) versus 13.8% (paclitaxel) (P < 0.0001), and was 37.7% (bevacizumab/paclitaxel) versus 16% (paclitaxel) (P < 0.0001) for patients with measurable disease only. The survival data are still immature [12] . Differences in the patient populations may help to explain the differences in results between the two phase III trials. Trial AVF2119 included a higher proportion of patients who had received chemotherapy, including those who had received both an anthracycline and a taxane. A greater number of HER2-positive patients were also enrolled in AVF2119, most of whom had previously received trastuzumab. Trial AVF2119 patients were generally more heavily pretreated than those enrolled in the E2100 trial. This may partly explain why the significant response rate improvement seen in this trial did not translate into a PFS benefit. Showing these results, it can be hypothesized that bevacizumab should be used as early as possible to obtain the maximum benefit. There are many other ongoing phase III trials that are testing the use of bevacizumab in combination with standard chemotherapy regimens. The AVADO trial is an ongoing randomized, double-blind, placebocontrolled, multicentre phase III trial that will randomize 705 patients to receive docetaxel at a dose of 100 mg/m 2 every 3 weeks with either placebo, bevacizumab 7.5 mg/kg or bevacizumab 15 mg/kg. The primary trial endpoint will be PFS. Secondary endpoints will include the OR rate, duration of response, time to treatment failure, overall survival, safety and quality of life. Another trial exploring bevacizumab in combination with standard regimens is the RIBBON-1 study, a phase III trial to be conducted in countries worldwide that will investigate further combinations of bevacizumab and chemotherapy. The primary trial endpoint is PFS. Investigators will assign patients to a chemotherapy regimen, including specified regimens of anthracycline-based combination chemotherapy, taxane (docetaxel or Abraxane™) every 3 weeks, or Xeloda. Patients are then randomized to receive bevacizumab (15 mg/kg every 2 weeks) or placebo. Another combination that is also being explored is bevacizumab plus trastuzumab. There is a strong rational for combining both antibodies as the different factors that bevacizumab and trastuzumab inhibit play important roles in tumour growth and progression. It has been shown that activation of the HER family of receptors induces VEGF expression and angiogenesis in cancer cell models [13] . These observations suggest that combined inhibition of VEGF and HER2 may enhance antitumour activity. The feasibility of combining bevacizumab with trastuzumab was evaluated in the phase I, open-label AVF2473s trial. A total of nine patients with HER2-positive advanced or MBC were treated in one of three cohorts. Data from this trial led to the recommendation of bevacizumab 10 mg/kg every 2 weeks for use in combination with trastuzumab 2 mg/kg weekly (after a loading dose of 4 mg/kg) in phase II trials. The maximum tolerated dose was not reached. Analyses of pharmacokinetic parameters showed that coadministration of bevacizumab and trastuzumab does not alter the pharmacokinetics of either agent, indicating no interaction between the two agents. The combination was well tolerated, with no grade 3/4 adverse events [14] . Besides the use of bevacizumab in the metastatic setting, it has been hypothesized that the greater benefit could be obtained when used in earlier stages. The progression of breast cancer is accompanied by the production of a wide array of proangiogenic growth factors that promote and support tumour growth. When tumours are small they secrete VEGF, which acts as a paracrine factor to induce endothelial cell proliferation and blood vessel formation, mediating tumour progression. As the tumour develops further, additional factors are also secreted [15] . This evidence suggests that the inhibition of VEGF may be more beneficial in earlier stages, as neoadjuvant or adjuvant treatment. There are many trials, planned and ongoing, exploring bevacizumab in the neoadjuvant setting. An ongoing, phase II trial of bevacizumab in combination with docetaxel in the neoadjuvant setting (AVF2307s) is being conducted in patients with locally unresectable breast cancer with or without metastasis. Patients receive bevacizumab 10 mg/kg every 2 weeks and docetaxel 35 mg/m 2 weekly for the first 6 weeks of an 8-week cycle. After two cycles, patients with stable disease or response, undergo surgery and radiotherapy, followed by further chemotherapy (not containing bevacizumab). The study objectives are to evaluate the efficacy and safety of neoadjuvant bevacizumab with docetaxel in breast cancer patients. Preliminary efficacy data showed that bevacizumab plus docetaxel reduces tumour vascular permeability and microvessel density [16] . Combined response data for both study arms revealed seven complete responses (14.3%), 32 partial responses (65.3%), five patients with stable disease and a further five with progressive disease. This gave an OR rate of 79.6%, with no difference between the study arms. Both PFS and OS were 40 months in the docetaxel arm and neither had been reached in the docetaxel plus bevacizumab arm [17] . TORI-B-02 is a phase II neoadjuvant trial currently being conducted at the University of California, Los Angeles. A total of 90 patients are being enrolled into four different treatment arms, in order to compare two different bevacizumab doses with placebo: Arm 1: bevacizumab 7.5 mg/kg, followed by six cycles of bevacizumab 7.5 mg/kg in combination with TAC (docetaxel, doxorubicin and cyclophosphamide) every 3 weeks; Arm 2: placebo 7.5 mg/kg, followed by six cycles of placebo 7.5 mg/kg in combination with TAC every 3 weeks; Arm 3: bevacizumab 15 mg/kg, followed by six cycles of bevacizumab 15 mg/kg in combination with TAC every 3 weeks; and Arm 4: placebo 15 mg/kg, followed by six cycles of placebo 15 mg/kg in combination with TAC every 3 weeks. Then, 28-42 days after receiving chemotherapy, patients eligible for surgery will undergo resection. After either receiving surgery or completing chemotherapy, patients in Arms 1 and 3 will receive bevacizumab at their previous dose until disease progression. Patients in Arms 2 and 4 will not receive further therapy before disease progression. The primary objectives of the TORI-B-02 trial are to evaluate the safety and toxicity of bevacizumab given as preoperative therapy to patients with stage II/III breast cancer in combination with the TAC regimen. Analysis of changes in HIF-1α levels will also be carried out, in order to compare tumour angiogenesis in patients given bevacizumab and placebo.
Other trial objectives include investigation of the clinical benefit of adding bevacizumab to TAC in the neoadjuvant setting. Parameters to be evaluated are the clinical objective response rate (complete response plus partial response), pathologic complete response rate and rate of breast-conserving surgery. As wound-healing complications have previously been reported in bevacizumab clinical trials, the effect of bevacizumab on postsurgical wound-healing will also be investigated as well as the rate of cardiac heart failure.
The most successful use of antiangiogenic therapy has been predicted to be in the adjuvant treatment, and there is a clear biologic basis and rationale for exploring bevacizumab in this clinical setting. A large proportion of patients with breast cancer have been reported to have primary tumours that overexpress VEGF, and overexpression of VEGF is associated with increased rates of relapse [18] . The trials planned with bevacizumab in the adjuvant setting will confirm the efficacy of adding an antiangiogenic therapy to standard combinations. The data from the trials currently ongoing will tell us the efficacy of combining bevacizumab with other drugs used in the metastatic setting, besides docetaxel or capecitabine, the exact role of bevacizumab in neoadjuvant and adjuvant settings, and perhaps it will be possible to identify which patients are most likely to benefit from VEGF-targeted therapies. The HER2 tyrosine kinase receptor is overexpressed in approximately 25% of invasive breast cancers, and has been associated with a poor prognosis [1] . Trastuzumab (Herceptin) and lapatinib (Tykerb) are the two therapies currently approved by the FDA for the treatment of HER2-overexpressing metastatic breast cancer. The majority of patients that initially respond to trastuzumab monoclonal antibody-based therapy develop progressive disease within 1 year of treatment initiation [2] . Preclinical studies have indicated several molecular mechanisms that may contribute to the development of trastuzumab resistance [3] . Increased signaling via the phosphatidylinositol 3-kinase/protein kinase B (or Akt) pathway could contribute to trastuzumab resistance due to activation of multiple receptor pathways. These include HER2-related receptors or non-HER receptors such as the insulin-like growth factor-I receptor, which appears to cross-talk to HER2 in resistant cells [4] . Additionally, loss of function of the tumor suppressor PTEN, the negative regulator of Akt, results in heightened Akt signaling that leads to decreased sensitivity to trastuzumab [5] . Decreased interaction between trastuzumab and its target receptor HER2, due to steric hindrance of the HER2 receptor by cell surface proteins, such as MUC-4 [6] , or by the presence of a truncated HER2 protein [7] , may block inhibitory actions of trastuzumab. Novel therapies targeted against these aberrant molecular pathways are being studied in laboratory and clinical settings, and offer hope that the efficacy and duration of response to trastuzumab can be greatly improved. Lapatinib (Tykerb) is a small molecule tyrosine kinase inhibitor that targets EGFR and HER-2 [8] . Clinical responses were observed in patients with HER2-overexpressing metastatic breast cancer [9] . A recent phase III randomized trial showed that a combination of lapatinib and capecitabine (Xeloda) was superior to capecitabine alone [10] Objective The proportion of node-negative breast cancer patients has been increasing with improvement of diagnostic modalities and early detection. However, there is a 20-30% recurrence in node-negative breast cancer. To identify the prognostic factors for node-negative breast cancers, we studied the impact of many clinico-pathologic parameters on the outcome of the node-negative breast cancer patients. Methods The data of 1,110 node-negative breast cancer patients who underwent curative surgery at the Severance Hospital, Yonsei University College of Medicine, were reviewed. The impact of many clinico-pathological parameters on the outcome was investigated. Univariate survival curves for disease-free survival and death were estimated using the Kaplan-Meier method: group differences in survival time were tested by the log-rank test. Multivariate Cox regression analysis was performed to compare and identify independent prognostic factors. Results The mean age was 47.2 years. The median follow-up was 88 months. Recurrence occurred in 161 patients; 64 patients with locoregional recurrences, 129 with systemic recurrences, and 32 with both. The 5-year overall survival rate was 93.3%. The rate of locoregional recurrence for a 10-year period was significantly lower in the mastectomy group compared with those in the breast conservation therapy group (94.7% versus 79.6%, P = 0.000). No other prognostic factors except age affected locoregional recurrence. There was less systemic recurrence in patients with age greater than 35, with histologic grade I, and with intraductal components greater than 20%. Thus, the 10-year distant relapse-free survival rates were 87.4% versus 79.8% (P = 0.039), 93.5% versus 85.5% (P = 0.024), and 94.4% versus 82.0% (P = 0.007), respectively. There was no statistical significance in the other prognostic factors that influence systemic recurrence. Conclusion Patient age, histologic grade, and presence of intraductal component were identified as independent prognostic factors in nodenegative breast cancer patients.
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Retreatment with trastuzumab in Her2-positive metastatic breast cancer patients: a clinical study 
Patients and methods
The clinical evolution of patients with Her2+ MBC diagnosed by IHC3+/FISH+, and treated with trastuzumab in several lines for the metastatic disease, has been studied retrospectively.
Results Twenty-four patients with Her2+ MBC were treated with several regimens containing trastuzumab alone or associated with chemotherapy and/or hormonotherapy. In the first line of treatment 12 RR (50%), 11 SD (45%), with a 95% clinical benefit, was observed. The patients received a second line obtaining 8 RR (33%), 15 SD (62%), with a clinical benefit of 95%. Seventeen patients were treated with a third line, 5 RR (29.4%) and 11 SD (64%) being observed, with a clinical benefit of 93%. Seven patients received a fourth line. In these, 2 RR and 4 SD, with a clinical benefit of 85%, were observed. Fifteen of the patients, with RE+, received hormonotherapy plus trastuzumab alone or with chemotherapy in one or more lines of treatment, obtaining 8 RR (53%) and 4 SD (26%), with a clinical benefit of 79%. Conclusion The association of herceptin with chemotherapy and/or hormonotherapy demonstrates a very active treatment in patients with Her2+ MBC. The benefit seems to continue in patients who already have received treatment with trastuzumab even in more than one regimen. Results The mean age of patients was 48.6 years (range 30-70). Of the 61 patients, BCS was achieved in 48 (79%) patients. On the core biopsy, four (6.5%) patients had grade I cancer, 26 (43%) had grade II cancer and 31 (51%) had grade III cancer. Final histology showed no invasive cancer in eight (13%) patients (seven DCIS, and complete pathological response in one patient). In the rest of the patients, four (6.5%) had grade I tumours, 26 (43%) had grade II tumours and 23 (38%) had grade III tumours. Overall, 14 patients (23%) showed a decrease in histological grade (see Table 1 ). Seven patients (11.5%) had a higher grade than the initial core.
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Conclusion
In our series of patients receiving NC for breast cancer, there is not only a significant downsizing (permitting BCS) but also a trend of downgrading of the tumour, and this is seen particularly in poorly differentiated tumours. The higher grade on final histology compared with the core could be due to an unrepresentative core biopsy in large tumours prior to NC. Objective To demonstrate that saline instillation is a safe and simple procedure for volume replacement after wide local excision in breast surgery.
Methods We performed a pilot study over a 12-month period at the Chase Breast Unit. One hundred and six patients who underwent wide local excision for breast cancer had saline instilled into the surgical cavity at the time of wound closure. This was to maintain the volume and shape of the breast after removal of significant amounts of tissue. We measured the volume instilled and monitored the wound and breast postoperatively at 1 week, 2 weeks and 3 months. As is our normal practice, all patients received perioperative antibiotics.
Results The volume of fluid instilled varied between 30 and 180 ml. The weight of tissue removed was in the range of 12-116 g. The fluid was retained within the cavity. However, in one case the wide local excision cavity unexpectedly communicated with the axillary clearance cavity and all the fluid was evacuated spontaneously through the axillary suction drain with a resultant visible reduction in the volume of the breast. There were no complications of saline instillation. In particular, there was no early or late infection in any of the 106 patients. None of the patients reported any additional discomfort or pain. There were no visible abnormalities apart from a subjective enhancement in the shape and volume of the breast. This improvement in shape and volume was maintained for the entire length of assessment (3 months). Conclusion Saline instillation is a simple and safe method of replacing volume after removal of significant amounts of breast tissue. Surprisingly, the benefits seem to persist. We are now proceeding to fully evaluate this technique in a formal prospective trial.
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A safety and efficacy study of bleomycin sulfate and electroporation in patients with metastatic or locally recurrent breast cancer 4-34) months. In the HER2-positive group the relapse rate was 20.8% in patients receiving antracycline-based CT versus 29.4% in patients receiving nonantracycline-based CT (P = 0.09). In the HER2-negative group the relapse rate was 33.3% in patients receiving antracycline-based CT versus 15.8% in patients receiving nonantracycline-based CT (P = 0.2). The subgroup of patients with HER2-negative, ER-negative tumors had the worst prognosis (relapse rate 45%) regardless of the CT received. Conclusion In patients with HER2 overexpression, antracycline-based CT produced a significantly lower relapse rate when compared with nonantracycline-based CT. In HER2-negative patients there was no benefit from antracycline-based CT compared with nonantracyclinebased CT. However, a longer follow-up period is needed to confirm the results. Methods We studied 159 patients with invasive breast cancer with axillary ultrasound and cytological puncture with fine needle of suspicious nodes before surgery. Suspicious nodes were those with at least one of the following signs: long to short axis ratio less than 1.5, absence of hilius and cortical disruption. If the results were compatible with metastasis, then we performed axillary lymphadenectomy; if it was found to be benign, then we conducted sentinel node biopsy.
P7
Results
In 54 patients (33.96%) FNA was positive. When we conducted axillary lymphadenectomy, 13 patients (24%) were found to have one positive node, seven patients (13%) two positive nodes, nine patients (16%) three positive nodes, and 25 patients (45%) more than three positive nodes. Conclusion Axillary study with ultrasound and FNA before surgery allows exclusion of a group of patients from sentinel node biopsy. With a median follow-up of 86 months, factors with independent prognostic value for disease-free survival by multivariate analysis included absence of estrogen receptors (P < 0.005), pN category (P < 0.01), presence of lymphovascular invasion (LVI; P < 0.005), and ECE (P < 0.001). An independent negative prognostic effect on overall survival was observed for absence of estrogen and progesterone receptors (P < 0.05), pN category (P < 0.05), and presence of LVI (P < 0.005) and ECE (P < 0.001).
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Conclusion ECE demonstrated a stronger statistical significance in predicting prognosis than the pN category and was also related to an increased risk of distant recurrences. We suggest that the decision on adjuvant therapy should consider the presence of ECE of axillary metastases and peritumoral LVI as indicators of high biological aggressiveness. Balancing the risks and benefits of irradiation, we continue to recommend that complete axillary irradiation is not routinely indicated after adequate axillary dissection. Results The highest proportion of successful gene amplifications was obtained with a DNA isolation procedure using proteinase K digestion with followed boiling. Three 5382insC mutations were identified from 16 archival familial patients (19%) and five mtDNA4977 deletions were detected from nine blood familial breast cancers by the multiplex PCR. The mtDNA4977 deletion was highly prevalent in peripheral blood (56%), but it was absent in the breast tissue of cancer cases. Furthermore, familial breast cancer tumors exhibited higher mitotic activity, higher polymorphism, lower necrosis, lower tubules, higher ERnegatives and PR-negatives and lower TP53-positives than nonfamilial cancers. Conclusion Our results demonstrate that DNA extracted by the simple boiling method with a microwave yielded higher proportions of successful gene amplifications than the DNA extraction kit. Furthermore, differences in successful gene amplification may be related to the size and number of the gene fragments amplified. Our analysis shows that testing of mtDNA4977 deletions and 5382insC in combination with morphological and immunohistochemical parameters may be an extremely effective and inexpensive tool in testing breast cancer patients aimed to identify individuals with high risk of familial breast cancers. . Preparation 'UNIMAG' represents a magnet-sensitive stabile suspension of magnetite nanoparticles (magnetic fluid). After the peritumoral injection of 'UNIMAG', magnetite nanoparticles will be absorbed by macrophages, which deliver them through the lymphatic capillaries to regional lymph nodes. This mechanism of magnetite nanoparticle transport underlies the new method of sentinel lymph node detection. Diversely to the other dyestuff agents used in this direction, magnetite nanoparticles actively filled lymphatic nodes and colored them in bold black. This significantly facilitates the atraumatic separation of lymph nodes during lymphadenectomy. Besides the intraoperative indication of lymphatic nodes, 'UNIMAG' provides the possibility of X-ray and ultrasound imaging of sentinel lymph nodes and performing their biopsy in the preoperative period. This assuredly helps in a better planning of the operation and considerably improves its radicalism. Even in the case of ideal surgical intervention it is impossible to remove all the microscopic lymphatic vessels and nodes that could be damaged by the tumor micrometastasis. In the field of high-frequency electromagnetic waves, the magnetite nanoparticles give us possibilities of local, distance hyperthermia on micrometastatic lesions. This minimizes the potentiality of development of postoperative recurrence and secondary metastatic processes. Objective Tamoxifen is an effective drug but its role in prevention is limited by its side-effect profile, particularly related to endometrial problems and thrombotic events. We present updated results on the comparison of side effects between active treatment and the follow-up period incorporating four additional years of follow-up. Methods In the International Breast Cancer Intervention Study I (IBIS-I) study, 7,154 women at increased risk of breast cancer were either randomised to tamoxifen 20 mg/day or placebo for 5 years. Women gave detailed information of any side effects at each 6-monthly followup visit and once a year after active treatment.
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Results During active treatment, large numbers of side effects were reported by participants in both treatment arms. However, the only major categories that showed differences were vasomotor and gynaecological side effects, which were about 12% higher in the tamoxifen group than the placebo group. Thromboembolic events were significantly higher in the tamoxifen group compared with the placebo Available online http://breast-cancer-research.com/supplements/9/S1 S22 group (85 versus 42, P < 0.001), whereas myocardial infarctions were reduced in women on tamoxifen during active treatment (2 versus 7, P = 0.09). Women on tamoxifen developed significantly more endometrial cancer during active treatment than women on placebo (12 versus 3, P = 0.02). After active treatment, most menopausal-like side effects decreased and the differences between the two treatment arms were not significant. Reports on vaginal discharge decreased after stopping tamoxifen. Thromboembolic events were similar between the two treatment arms after active treatment (32 versus 26, P = 0.4). No significant difference in endometrial cancer between the two treatment groups was found during follow-up time (8 versus 5, P = 0.4).
Conclusion Although large numbers of side effects were reported, tamoxifen was well tolerated and no new safety concerns were identified. For most side effects no significant difference between treatment groups was found after ceasing tamoxifen. Materials and methods Bone marrow (BM) aspirates were taken 2-4 years following chemotherapy from 39 patients who had entered a trial comparing high-dose chemotherapy (n = 17) with standard chemotherapy (n = 22). The BM was tested for the presence of CK19-positive cells using ICC and QPCR. We compared this with 20 lowrisk (T1N0) patients. Results See Table 1 . A total of 232 aspirates were analysed from the high-risk patients and 100 from the T1N0 patients. The number of patients positive was therefore approximately the same irrespective of therapy in the high-risk patients, and the levels of positivity were not significantly different (PCR, P = 0.078; and ICC, P = 0.253). The levels of positivity, however, were higher in the high-risk patients than in the low-risk patients.
P18 Minimal residue disease (MRD)
A
Conclusion
We have demonstrated that: (a) patients who received high-dose and standard chemotherapy showed similar results, (b) patients with a low-risk of relapse had markedly lower values as compared with high-risk primary breast cancer patients, and (c) micrometastases persist in a substantial proportion of patients. Background Seroma formation after axillary lymph node dissection in breast cancer remains a problem despite many efforts to reduce surgery-related morbidity. The aim of the present study was to evaluate the impact of a fibrin-glue-coated collagen patch (Tachosil ® ; Nycomed Laboratory, Denmark) to reduce the volume and duration of postoperative axillary drainage, the duration of hospital stay, and procedural safety.
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Patients and methods Twenty-five patients with breast cancer were included in this prospective study. All patients underwent breast surgery including lumpectomy or mastectomy followed by axillary lymph node dissection (Berg Level I and II). In 13 patients, a surgical haemostasis sponge Tachosil ® was applied from the apex axillae to the thoracic longus nerve and 12 had standard closure of the axillary lymphadenectomy area. Patients did not differ with respect to general characteristics, such as age, body mass index, treatment modality, and tumor stage distribution. There were six mastectomy and five lumpectomy operations in the Tachosil ® group, and seven mastectomy and four lumpectomy surgeries in the control group. The mean number of removed lymph nodes was 11.9 in the Tachosil ® group with a mean of 1.2 metastatics nodes, and was 12.2 in the control group with a mean of 2.5 metastatic nodes.
Results The mean duration of axillary drainage was 3.3 days in the Tachosil ® group and 5.5 days in the control group. The mean total drainage volume was 246 ml in the Tachosil ® group and 470 ml in the standard closure group. The mean length of postoperative hospital stay was 3.5 days in the Tachosil ® group and 5.5 days in the standard closure group. Seroma formation after drain removal was found in four patients with a mean of drainage volume of 161 ml in the Tachosil ® group, and in five patients with a mean of drainage volume of 517 ml in the standard closure group. No intolerance of the product was described. Conclusion The use of Tachosil ® in the axillary area in patients with breast cancer requiring axillary dissection seems to reduce the volume and duration of postoperative axillary drainage, the duration of hospital stay, and the frequency and volume of seroma after axillary drainage. Larger series are required to confirm these results.
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First clinical results on the potential of intraoperative imaging for sentinel lymph node biopsy in breast cancer Objective To compare the hand-held camera (POCI) with a lymphoscintigraphy in order to precisely localize SLNs in patients with breast cancer requiring SLN biopsy. Methods The SLN protocol consisted of a peritumoral injection of 160 MBq 99m Tc-labeled nano-colloids performed 2 hours before the lymphoscintigraphy, which is realized preoperatively using a conventional single-head gamma camera and then the hand-held POCI camera (field-of-view, 13 cm 2 ) (Figure 1 ). The day after, in the operating room, the patients undergo one blue-dye subcutaneous tumoral injection. Before incision the surgeon first uses the POCI to perform an intraoperative lymphoscintigraphy and then the counting probe (Europrobe CsI, Eurorad) for transcutaneous SLN prelocalizations. The POCI camera was slowly moved on the skin until SLN identification. The axillary area was scanned with the POCI camera with 10-second acquisition images. SLN detection was defined as positive on the basis of a local radioactivity increase in the intraoperative images of the surveyed region. The SLN excision biopsy was guided, following the established procedure, using the counting probe and blue dye. Finally, a complementary scanning procedure was performed with the POCI directly in the operative wound before skin closure to confirm complete excision or to detect some residuals SLNs. The number and the localization of SLNs obtained by both intraoperative detectors are compared with those obtained the day before with the conventional gamma camera. Results To date, 33 patients (mean age: 64 years) have been included in this clinical protocol. A SLN was identified by lymphoscintigraphy in 31/33 patients (94%), versus 30/33 (90.9%) with the POCI (P > 0.3). The mean number of SLNs identified by lymphoscintigraphy was 1.6 (range: 0-4), versus 1.8 (range: 0-4) with the POCI (Table 1 ). The day of the surgery, at least one SLN (mean: 1.9; range: 0-4) was identified Available online http://breast-cancer-research.com/supplements/9/S1 
Figure 1 (abstract P22)
Preoperative image by POCI showing two hot sentinel nodes.
